Page 14 - 南京医科大学学报自然科学版
P. 14
第42卷第9期
·1208 · 南 京 医 科 大 学 学 报 2022年9月
hypoxic pulmonary hypertension[J]. J Cardiovasc Phar⁃ nary arterial hypertension rats[J]. J Med Chem,2018,61
macol Ther,2021,26(6):665-676 (4):1474-1482
[5] ALI S,SOLANO A S,GONZALES A L,et al. Nitric oxide [14] 程玉生. 吸入CDDO⁃NO对野百合碱诱导的大鼠肺动脉
signals through IRAG to inhibit TRPM4 channels and di⁃ 高压的作用[D]. 南京:南京医科大学,2018
late cerebral arteries[J]. Function(Oxf),2021,2(6): [15] MASULLO M,PIZZA C,PIACENTE S. Oleanane deriva⁃
zqab051 tives for pharmaceutical use:a patent review(2000⁃2016)
[6] NAHAR K,RASHID J,ABSAR S,et al. Liposomal aero⁃ [J]. Expert OpinTher Pat,2017,27(3):237-255
sols of nitric oxide(NO)donor as a long⁃acting substitute [16] DIANAT M,RADAN M,MARD S A,et al. Contribution
for the ultra⁃short⁃acting inhaled NO in the treatment of of reactive oxygen species via the OXR1 signaling path⁃
PAH[J]. Pharm Res,2016,33(7):1696-1710 way in the pathogenesis of monocrotaline⁃induced pulmo⁃
[7] YU B,ICHINOSE F,BLOCH D B,et al. Inhaled nitric nary arterial hypertension:the protective role of crocin
oxide[J]. Br J Pharmacol,2019,176(2):246-255 [J]. Life Sci,2020,256:117848
[8] PUIKUAN K,CHUNYU Z,JIN F,et al. Inhalation of nebu⁃ [17] SIMENAUER A,ASSEFA B,RIOS⁃OCHOA J,et al. Re⁃
lized nitroglycerin,a nitric oxide donor,for the treatment pression of Nrf2/ARE regulated antioxidant genes and
of pulmonary hypertension induced by high pulmonary dysregulation of the cellular redox environment by the
blood flow[J]. Heart Vessels,2006,21(3):169-179 HIV transactivator of transcription[J]. Free Radic Biol
[9] 张明发,沈雅琴. 熊果酸和齐墩果酸抗肝脂肪变和纤维 Med,2019,141:244-252
化作用研究进展[J]. 药物评价研究,2017,40(2):270- [18] KUNNUMAKKARA A B,SHABNAM B,GIRISA S,et al.
278 Inflammation,NF⁃κB,and chronic diseases:How are they
[10] WANG Y Y,YANG Y X,ZHE H,et al. Bardoxolone methyl linked?[J]. Crit Rev Immunol,2020,40(1):1-39
(CDDO⁃Me)as a therapeutic agent:an update on its phar⁃ [19] HONG J,ARNESON D,UMAR S,et al. Single⁃cell study
macokinetic and pharmacodynamic properties[J]. Drug of two rat models of pulmonary arterial hypertension re⁃
Des Devel Ther,2014,8:2075-2088 veals connections to human pathobiology and drug reposi⁃
[11] BORELLA R,FORTI L,GIBELLINI L,et al. Synthesis tioning[J]. Am J Respir Crit Care Med,2021,203(8):
and anticancer activity of CDDO and CDDO ⁃ Me,two 1006-1022
derivatives of natural triterpenoids[J]. Molecules,2019, [20] LÁZÁR Z,MÉSZÁROS M,BIKOV A. The nitric oxide
24(22):4097 pathway in pulmonary arterial hypertension:pathomecha⁃
[12] 邵成杰,孔 辉,曾晓宁,等. 尼可地尔抑制野百合碱诱 nism,biomarkers and drug targets[J]. Curr Med Chem,
导的肺动脉高压小鼠肺血管重构[J]. 南京医科大学学 2020,27(42):7168-7188
报(自然科学版),2017,37(8):943-948 [21] RADI R. Oxygen radicals,nitric oxide,and peroxynitrite:
[13] CHENG Y,GONG Y,QIAN S,et al. Identification of a redox pathways in molecular medicine[J]. Proc Natl
novel hybridization from isosorbide 5 ⁃ mononitrate and Acad Sci U S A,2018,115(23):5839-5848
bardoxolone methyl with dual activities of pulmonary [收稿日期] 2022-02-24
vasodilation and vascular remodeling inhibition on pulmo⁃ (本文编辑:陈汐敏)